A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism

被引：0
作者：
Michael Chez
Shawn Kile
Christopher Lepage
Carol Parise
Bobbie Benabides
Andrea Hankins
机构：
[1] Sutter Neuroscience Institute,
[2] Sutter Institute for Medical Research,undefined
[3] Northwest Passage,undefined
来源：
Journal of Autism and Developmental Disorders | 2020年 / 50卷
关键词：
Autism spectrum disorder; Adults; Dextromethorphan; Quinidine; Irritability; Aggression; Placebo controlled crossover trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18–60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo for 8 weeks, washed out for 4 weeks, then crossed over to the opposite treatment. There were no serious adverse events. Subjects were significantly lower on the Aberrant Behavioral Checklist for Irritability (ABC-IR) (F1,10 = 7.42; p = 0.021). Improvements in aggression and Clinical Global Impression were also seen. The findings suggest that DM/Q is well-tolerated and associated with improvements in irritability and aggression in adults with autism.
引用
收藏
页码：1532 / 1538
页数：6
相关论文
共 102 条
[1]  
Aman M(2015)Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-Month follow-up after 8-week placebo-controlled trial Journal of Child and Adolescent Psychopharmacology 25 482-493
[2]  
Rettiganti M(2018)Prevalence of autism spectrum disorder among children aged 8 years—Autism and developmental disabilities monitoring network, 11 sites, United States, 2014 MMWR Surveillance Summaries 67 1-23
[3]  
Nagaraja HN(1985)Histoanatomic observations of the brain in early infantile autism Neurology 35 866-874
[4]  
Hollway JA(2007)Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability Journal of Child Neurology 22 574-579
[5]  
McCracken J(2016)PRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury BMC Neurology 16 89-35
[6]  
McDougle CJ(2005)The overt aggression scale for rating aggression in outpatient youth with autistic disorder: Preliminary findings Journal of Neuropsychiatry and Clinical Neurosciences 17 29-665
[7]  
Baio J(2001)Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder Journal of the American Academy of Child and Adolescent Psychiatry 40 658-1119
[8]  
Wiggins L(2009)A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder Journal of the American Academy of Child and Adolescent Psychiatry 48 1110-183
[9]  
Christensen DL(2013)Tolerability and safety profile of risperidone in a sample of children and adolescents International Clinical Psychopharmacology 28 177-321
[10]  
Maenner MJ(2002)Risperidone in children with autism and serious behavioral problems New England Journal of Medicine 347 314-1347
12345678910